These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 9598692

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Sodium valproate and ornithine carbamyl transferase deficiency.
    Tripp JH, Hargreaves T, Anthony PP, Searle JF, Miller P, Leonard JV, Patrick AD, Oberholzer VG.
    Lancet; 1981 May 23; 1(8230):1165-6. PubMed ID: 6112522
    [No Abstract] [Full Text] [Related]

  • 23. Status epilepticus secondary to hyperammonaemia: a late presentation of an undiagnosed urea cycle defect.
    Beddoes P, Nerone G, Tai C.
    BMJ Case Rep; 2021 May 31; 14(5):. PubMed ID: 34059532
    [Abstract] [Full Text] [Related]

  • 24. Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting.
    Dealberto MJ.
    Int Clin Psychopharmacol; 2007 Nov 31; 22(6):330-7. PubMed ID: 17917551
    [Abstract] [Full Text] [Related]

  • 25. Sodium valproate-related hyperammonaemic encephalopathy.
    Pegg EJ, Zaman F.
    BMJ Case Rep; 2014 Apr 10; 2014():. PubMed ID: 24722719
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Amino acid and DNA analyses in a family with ornithine transcarbamylase deficiency.
    Hou JW, Wang TR.
    J Formos Med Assoc; 1996 Feb 10; 95(2):144-7. PubMed ID: 9064003
    [Abstract] [Full Text] [Related]

  • 28. [Cerebral edema with hyperammonemia in valpromide poisoning. Manifestation in an adult, of a partial deficit in type I carbamylphosphate synthetase].
    Bourrier P, Varache N, Alquier P, Rabier D, Kamoun P, Lorre G, Alhayek G.
    Presse Med; 1988 Nov 05; 17(39):2063-6. PubMed ID: 2974563
    [Abstract] [Full Text] [Related]

  • 29. Long-term treatment of girls with ornithine transcarbamylase deficiency.
    Maestri NE, Brusilow SW, Clissold DB, Bassett SS.
    N Engl J Med; 1996 Sep 19; 335(12):855-9. PubMed ID: 8778603
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Neurological deterioration in patients with urea cycle disorders under valproate therapy--a cause for concern.
    Sewell AC, Böhles HJ, Herwig J, Demirkol M.
    Eur J Pediatr; 1995 Jul 19; 154(7):593-4. PubMed ID: 7556337
    [No Abstract] [Full Text] [Related]

  • 33. Valproate as a cause of hyperammonemia in heterozygotes with ornithine-transcarbamylase deficiency.
    Leão M.
    Neurology; 1995 Mar 19; 45(3 Pt 1):593-4. PubMed ID: 7898728
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Valproate-induced hyperammonemia.
    Batshaw ML, Brusilow SW.
    Ann Neurol; 1982 Mar 19; 11(3):319-21. PubMed ID: 6807193
    [Abstract] [Full Text] [Related]

  • 39. A case of ornithine transcarbamylase deficiency with Rett syndrome manifestations.
    Hyman SL, Batshaw ML.
    Am J Med Genet Suppl; 1986 Mar 19; 1():339-43. PubMed ID: 3087194
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.